Cardiovascular Risk Reduction in Atrial Fibrillation Trial
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) is a serious public health problem because of its increasing
incidence and prevalence in the aging population. AF is associated with elevated risks of
death, stroke, coronary event, heart failure, cognitive decline, and chronic kidney disease.
To identify preventive interventions for major cardiovascular events beyond effective
anticoagulation should be a major priority in the treatment of AF patients. The CRAFT study
is a 2-arm, multicenter, randomized clinical trial designed to test whether intensive blood
pressure control will reduce the risk of major cardiovascular events in AF patients.
Phase:
N/A
Details
Lead Sponsor:
Beijing Anzhen Hospital
Collaborators:
Fukuoka University Heart Health Research Centre The George Institute for Global Health, Australia The George Institute for Global Health, China